| pubmed-article:11578907 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11578907 | lifeskim:mentions | umls-concept:C0663182 | lld:lifeskim |
| pubmed-article:11578907 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:11578907 | lifeskim:mentions | umls-concept:C1521827 | lld:lifeskim |
| pubmed-article:11578907 | lifeskim:mentions | umls-concept:C1548779 | lld:lifeskim |
| pubmed-article:11578907 | lifeskim:mentions | umls-concept:C1947902 | lld:lifeskim |
| pubmed-article:11578907 | lifeskim:mentions | umls-concept:C2827499 | lld:lifeskim |
| pubmed-article:11578907 | lifeskim:mentions | umls-concept:C1515655 | lld:lifeskim |
| pubmed-article:11578907 | lifeskim:mentions | umls-concept:C1167624 | lld:lifeskim |
| pubmed-article:11578907 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:11578907 | pubmed:dateCreated | 2001-10-1 | lld:pubmed |
| pubmed-article:11578907 | pubmed:abstractText | The syntheses, radiolabeling, antibody conjugation, and in vivo evaluation of new linkers for 211At labeling of humanized anti-Tac (Hu-anti-Tac), an antibody to the alpha-chain of the IL-2 receptor (IL-2Ralpha) shown to be a useful target for radioimmunotherapy are described. Synthesis of the organometallic linker precursors is accomplished by reaction of the corresponding bromo- or iodoaryl esters with bis(tributyltin) in the presence of a palladium catalyst. Subsequent conversion to the corresponding N-succinimidyl ester and labeling with 211At of two new linkers, N-succinimidyl 4-[211At]astato-3-methylbenzoate and N-succinimidyl N-(4-[211At]astatophenethyl)succinamate (SAPS), together with the previously reported N-succinimidyl 4-[211At]astatobenzoate and N-succinimidyl 3-[211At]astato-4-methylbenzoate, are each conjugated to Hu-anti-Tac. The plasma survival times of these conjugates are compared to those of directly iodinated (125I) Hu-anti-Tac. The N-succinimidyl N-(4-[211At]astatophenethyl)succinamate compound (SAPS) emerged from this assay as the most viable candidate for 211At-labeling of Hu-anti-Tac. SAPS, along with the directly analogous radio-iodinated reagent, N-succinimidyl N-(4-[125I]astatophenethyl)succinamate (SIPS), are evaluated in a biodistribution study along with directly iodinated (125I) Hu-anti-Tac. Blood clearance and biological accretion results indicate that SAPS is a viable candidate for further evaluation for radioimmunotherapy of cancer. | lld:pubmed |
| pubmed-article:11578907 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11578907 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11578907 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11578907 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11578907 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11578907 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11578907 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11578907 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11578907 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11578907 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11578907 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:11578907 | pubmed:issn | 0969-8051 | lld:pubmed |
| pubmed-article:11578907 | pubmed:author | pubmed-author:EckelmanW CWC | lld:pubmed |
| pubmed-article:11578907 | pubmed:author | pubmed-author:WaldmannT ATA | lld:pubmed |
| pubmed-article:11578907 | pubmed:author | pubmed-author:YauPP | lld:pubmed |
| pubmed-article:11578907 | pubmed:author | pubmed-author:HoranHH | lld:pubmed |
| pubmed-article:11578907 | pubmed:author | pubmed-author:ZhangMM | lld:pubmed |
| pubmed-article:11578907 | pubmed:author | pubmed-author:ZhangZZ | lld:pubmed |
| pubmed-article:11578907 | pubmed:author | pubmed-author:GarmestaniKK | lld:pubmed |
| pubmed-article:11578907 | pubmed:author | pubmed-author:PhillipsK EKE | lld:pubmed |
| pubmed-article:11578907 | pubmed:author | pubmed-author:GansowO AOA | lld:pubmed |
| pubmed-article:11578907 | pubmed:author | pubmed-author:BrechbielM... | lld:pubmed |
| pubmed-article:11578907 | pubmed:author | pubmed-author:HerringBB | lld:pubmed |
| pubmed-article:11578907 | pubmed:author | pubmed-author:PlascjakP SPS | lld:pubmed |
| pubmed-article:11578907 | pubmed:author | pubmed-author:SchwarzU PUP | lld:pubmed |
| pubmed-article:11578907 | pubmed:author | pubmed-author:BeitzelM PMP | lld:pubmed |
| pubmed-article:11578907 | pubmed:author | pubmed-author:YordanovA TAT | lld:pubmed |
| pubmed-article:11578907 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11578907 | pubmed:volume | 28 | lld:pubmed |
| pubmed-article:11578907 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11578907 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11578907 | pubmed:pagination | 845-56 | lld:pubmed |
| pubmed-article:11578907 | pubmed:dateRevised | 2003-11-14 | lld:pubmed |
| pubmed-article:11578907 | pubmed:meshHeading | pubmed-meshheading:11578907... | lld:pubmed |
| pubmed-article:11578907 | pubmed:meshHeading | pubmed-meshheading:11578907... | lld:pubmed |
| pubmed-article:11578907 | pubmed:meshHeading | pubmed-meshheading:11578907... | lld:pubmed |
| pubmed-article:11578907 | pubmed:meshHeading | pubmed-meshheading:11578907... | lld:pubmed |
| pubmed-article:11578907 | pubmed:meshHeading | pubmed-meshheading:11578907... | lld:pubmed |
| pubmed-article:11578907 | pubmed:meshHeading | pubmed-meshheading:11578907... | lld:pubmed |
| pubmed-article:11578907 | pubmed:meshHeading | pubmed-meshheading:11578907... | lld:pubmed |
| pubmed-article:11578907 | pubmed:meshHeading | pubmed-meshheading:11578907... | lld:pubmed |
| pubmed-article:11578907 | pubmed:meshHeading | pubmed-meshheading:11578907... | lld:pubmed |
| pubmed-article:11578907 | pubmed:meshHeading | pubmed-meshheading:11578907... | lld:pubmed |
| pubmed-article:11578907 | pubmed:meshHeading | pubmed-meshheading:11578907... | lld:pubmed |
| pubmed-article:11578907 | pubmed:meshHeading | pubmed-meshheading:11578907... | lld:pubmed |
| pubmed-article:11578907 | pubmed:meshHeading | pubmed-meshheading:11578907... | lld:pubmed |
| pubmed-article:11578907 | pubmed:meshHeading | pubmed-meshheading:11578907... | lld:pubmed |
| pubmed-article:11578907 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11578907 | pubmed:articleTitle | Preparation and in vivo evaluation of linkers for 211At labeling of humanized anti-Tac. | lld:pubmed |
| pubmed-article:11578907 | pubmed:affiliation | Radiation Oncology Branch, Division of Clinical Sciences, National Cancer Institute, Department of Nuclear Medicine, Bethesda, MD 20892, USA. | lld:pubmed |
| pubmed-article:11578907 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11578907 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11578907 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11578907 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11578907 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11578907 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11578907 | lld:pubmed |
